To accelerate development of molecular targeted systemic radiotherapy (SR, PRRT) based on its clinical stage technology
Edinburgh, United Kingdom – 17 December 2019 – Edinburgh Molecular Imaging Ltd (EMI), a company developing theragnostic agents targeting cancer, today announces the closing of a £3.1 million financing, which will be used to advance our new molecular targeted systemic radiotherapy agents, EMT‑100 and EMT‑101 ready for clinic development. Current investors and one new investor supported the round.
EMT‑100 and EMT‑101 have been developed as therapeutic agents from the company’s clinical stage imaging agent EMI‑137 and hence may present a fast track opportunity to enter the exciting and rapidly developing arena of systemic radiotherapy.
EMT‑100 and EMT‑101 are comprised of peptides targeting c-Met, conjugated to a radionuclide. c‑MET is significantly over-expressed by many tumours compared with healthy tissue and EMI-100/101 selectively target c-MET to deliver a lethal dose of radiation directly to tumour cells, with minimal impact on surrounding tissues. They offer the potential to target many solid tumours as well providing new treatment options for currently difficult to treat cancers.